PL2437606T3 - Compositions and methods for increasing telomerase activity - Google Patents

Compositions and methods for increasing telomerase activity

Info

Publication number
PL2437606T3
PL2437606T3 PL10778210T PL10778210T PL2437606T3 PL 2437606 T3 PL2437606 T3 PL 2437606T3 PL 10778210 T PL10778210 T PL 10778210T PL 10778210 T PL10778210 T PL 10778210T PL 2437606 T3 PL2437606 T3 PL 2437606T3
Authority
PL
Poland
Prior art keywords
compositions
methods
telomerase activity
increasing telomerase
increasing
Prior art date
Application number
PL10778210T
Other languages
Polish (pl)
Inventor
Calvin B. Harley
Soo-Peang Khor
Mahesh Ramaseshan
Premchandran H. Ramiya
Zhu Zhen Pirot
Steven Fauce
Tong Lin
Original Assignee
Telomerase Activation Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telomerase Activation Sciences, Inc. filed Critical Telomerase Activation Sciences, Inc.
Publication of PL2437606T3 publication Critical patent/PL2437606T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K999/00—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group
    • H05K999/99—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group dummy group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
PL10778210T 2009-05-18 2010-05-17 Compositions and methods for increasing telomerase activity PL2437606T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17930509P 2009-05-18 2009-05-18
EP10778210.4A EP2437606B1 (en) 2009-05-18 2010-05-17 Compositions and methods for increasing telomerase activity

Publications (1)

Publication Number Publication Date
PL2437606T3 true PL2437606T3 (en) 2017-07-31

Family

ID=43069009

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10778210T PL2437606T3 (en) 2009-05-18 2010-05-17 Compositions and methods for increasing telomerase activity

Country Status (16)

Country Link
US (4) US8481721B2 (en)
EP (1) EP2437606B1 (en)
JP (1) JP5830013B2 (en)
CN (2) CN102448308B (en)
CA (1) CA2795981C (en)
CY (1) CY1118073T1 (en)
DK (1) DK2437606T3 (en)
ES (1) ES2596631T3 (en)
HR (1) HRP20161324T1 (en)
HU (1) HUE030253T2 (en)
LT (1) LT2437606T (en)
PL (1) PL2437606T3 (en)
PT (1) PT2437606T (en)
SI (1) SI2437606T1 (en)
SM (1) SMT201600332B (en)
WO (1) WO2010135247A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481721B2 (en) * 2009-05-18 2013-07-09 Telomerase Activation Sciences, Inc. Compositions and methods for increasing telomerase activity
WO2015029340A1 (en) * 2013-08-29 2015-03-05 パナソニック株式会社 Method for measuring telomerase activity
CN108498521B (en) * 2017-02-24 2020-05-05 北京大学 Application of cycloastragenol in preparation of medicine for inhibiting abdominal aortic aneurysm
TR201714942A2 (en) * 2017-10-04 2019-04-22 Ege Ueniversitesi Rektoerluegue PRODUCTION METHOD OF TELOMERASE ACTIVATORS AND TELOMERASE ACTIVATORS OBTAINED BY THIS METHOD
US20220025352A1 (en) 2018-10-02 2022-01-27 Stemon Inc. Method for extending telomere of cell
KR102209234B1 (en) * 2018-10-02 2021-02-01 주식회사 스템온 Methods for lengthening telomeres in cells
WO2020071665A2 (en) 2018-10-02 2020-04-09 주식회사 스템온 Composition for extending telomere of cell and preparation method therefor
CN109342619A (en) * 2018-11-14 2019-02-15 神威药业集团有限公司 Stilbene Huang leads to the measuring method of Astragaloside content in secret soft capsule
MX2019006749A (en) 2019-06-10 2022-11-28 Univ Mexico Nac Autonoma Cellular senescence activating compounds.
CN112457362B (en) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 Halogenated tetracyclic triterpene derivative and preparation and application thereof
CN117247339B (en) * 2023-11-16 2024-03-12 潍坊富邦药业有限公司 Preparation method of alkylamine derivative
CN117736980A (en) * 2024-02-20 2024-03-22 广东先康达生物科技有限公司 Induced differentiation medium for transforming adipose-derived mesenchymal stem cells into chondrocytes and application thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1392902A (en) 1972-01-25 1975-05-07 Lorenzini Sas Inst Biochim Aminoesters of cardenolides
DE3510555A1 (en) * 1985-03-21 1986-09-25 Schering AG, 1000 Berlin und 4709 Bergkamen ESTRIOLESTER
JPS6212791A (en) 1986-07-18 1987-01-21 Osaka Chem Lab Astragali radix saponin, isolation and use thereof
IT1259645B (en) 1992-04-10 1996-03-25 Solis Srl METHOD FOR DETECTING THE DENSITY CHANGE OF A FABRIC AND DEVICE FOR ITS IMPLEMENTATION
US5629154A (en) * 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US6007989A (en) 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
FR2695561B1 (en) * 1992-09-17 1994-12-02 Lvmh Rech Gie Cosmetic or dermatological composition containing at least one ginsenoside-type saponin, and its applications, in particular for hair care.
US5863726A (en) * 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
AT402890B (en) 1994-03-16 1997-09-25 Berbi Gmbh USE OF NOTOGINSENOSIDE R1 IN THE PRODUCTION OF MEDICINAL PRODUCTS
US6162459A (en) * 1995-02-24 2000-12-19 National Science Council Acyclovir transdermal delivery system
AUPN411195A0 (en) * 1995-07-10 1995-08-03 Cathay Herbal Laboratories Pty Ltd Medicinal composition
CN1079265C (en) 1995-08-01 2002-02-20 裴国增 Lucid ganoderma oral liquid and preparation process
US5785977A (en) * 1996-02-07 1998-07-28 Breithbarth; Richard Non-metallic microparticle carrier materials
US5916565A (en) * 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
TW452494B (en) * 1996-03-12 2001-09-01 Jang De Shan Herbal composition for stimulating blood circulation
US5900226A (en) * 1997-04-09 1999-05-04 Uop Llc Drying agents for non-foamed polyurethanes
JPH1036388A (en) 1996-07-25 1998-02-10 Kureha Chem Ind Co Ltd Synthesis inhibitor containing ginsenoside of protein belonging to hsp 27 family
US20020044977A1 (en) * 1997-01-28 2002-04-18 Graeme A. Close Centipeda plant extract
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
NZ528906A (en) 1997-05-14 2005-06-24 Atherogenics Inc Compounds and methods for the inhibition of the expression of VCAM-1
AU748441B2 (en) * 1997-09-05 2002-06-06 Procter & Gamble Company, The Cleansing and conditioning products for skin or hair with improved deposition of conditioning ingredients
EP1011630B2 (en) * 1997-09-12 2008-10-15 The Procter & Gamble Company Cleansing and conditioning article for skin or hair
JP2002500040A (en) 1998-01-12 2002-01-08 コールド スプリング ハーバー ラボラトリー Extending cell life, methods and reagents
GB9815177D0 (en) * 1998-07-13 1998-09-09 King S College London Treatment of skin disorders
WO2000008135A1 (en) 1998-08-09 2000-02-17 Board Of Regents, The University Of Texas System Methods and compositions for inhibiting or stimulating telomerase assembly
JP2002530436A (en) 1998-11-25 2002-09-17 ジェネティカ インコーポレイテッド Method and reagent for enhancing proliferation ability and preventing replication senescence
JP2000204091A (en) 1999-01-13 2000-07-25 Nippon Suisan Kaisha Ltd Novel benzodioxol derivative
JP2000229827A (en) 1999-02-05 2000-08-22 Kose Corp Skin lotion
JP2000229834A (en) 1999-02-10 2000-08-22 Kanebo Ltd Cosmetic
AUPQ127399A0 (en) 1999-06-29 1999-07-22 Guangzhou University Of Traditional Chinese Medicine Compositions and methods for treating or preventing osteoporosis
CA2307393A1 (en) * 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US6277396B1 (en) * 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
CN1172677C (en) * 2000-07-14 2004-10-27 复旦大学附属中山医院 Application of astragalin A in preparing medicinal composition
WO2002007732A2 (en) 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Use of panaxatriol for stimulation angiogenesis
WO2002026762A1 (en) * 2000-09-29 2002-04-04 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
JP2004509972A (en) 2000-09-29 2004-04-02 リージェンツ　オブ　ザ　ユニバーシティ　オブ　ミネソタ Triterpenes with fungicidal activity against yeast
US6696094B2 (en) * 2000-10-18 2004-02-24 Tzu-Sheng Wu Herbal pharmaceutical composition for treatment of HIV/AIDS patients
CN1369276A (en) * 2001-02-12 2002-09-18 徐秀荣 Composition and method for effectively losing body weight
WO2002091999A2 (en) 2001-05-09 2002-11-21 Geron Corporation Treatment for wounds
US20020182272A1 (en) * 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
JP2003089687A (en) 2001-07-03 2003-03-28 Tanabe Seiyaku Co Ltd New butadiene derivative, method for producing the same and synthetic intermediate therefor
WO2003004473A1 (en) 2001-07-03 2003-01-16 Tanabe Seiyaku Co., Ltd. Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US20030108629A1 (en) * 2001-07-17 2003-06-12 Chou Wen Hsien Compositions and methods for prostate and kidney health and disorders, an herbal preparation
CN1406585A (en) 2001-09-07 2003-04-02 中国科学院上海药物研究所 Medicinal composition for viral myocarditis
JP2003160497A (en) 2001-11-22 2003-06-03 Toshin Kagaku Kk Skin care preparation
CN1236803C (en) 2002-03-20 2006-01-18 郑国芃 Rheuamtism treating Chinese medicine
WO2004064759A2 (en) * 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
WO2004089357A2 (en) * 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
WO2004112724A2 (en) 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
AP2280A (en) 2003-06-23 2011-10-31 Geron Corp Compositions and methods for increasing telomeraseactivity.
WO2005000248A2 (en) * 2003-06-25 2005-01-06 Geron Corporation Compositions and methods for skin conditioning
US20070122501A1 (en) 2003-06-27 2007-05-31 Hong Kong University Of Science And Technology Formulations containing astragalus extracts and uses thereof
CN100384830C (en) 2006-01-12 2008-04-30 天津药物研究院 Derivative of cyclo membranousol kind and application thereof
PT2152663E (en) 2007-06-04 2014-06-03 Univ Ben Gurion Tri-aryl compounds and compositions comprising the same
US8481721B2 (en) * 2009-05-18 2013-07-09 Telomerase Activation Sciences, Inc. Compositions and methods for increasing telomerase activity

Also Published As

Publication number Publication date
US8481721B2 (en) 2013-07-09
SI2437606T1 (en) 2016-10-28
US20140088055A1 (en) 2014-03-27
US20160318973A1 (en) 2016-11-03
US9403866B2 (en) 2016-08-02
ES2596631T3 (en) 2017-01-11
WO2010135247A1 (en) 2010-11-25
US20180280413A1 (en) 2018-10-04
CN102448308A (en) 2012-05-09
CN104447936A (en) 2015-03-25
JP2012532092A (en) 2012-12-13
CA2795981C (en) 2017-06-27
PT2437606T (en) 2016-09-22
HUE030253T2 (en) 2017-04-28
CN102448308B (en) 2014-08-06
HRP20161324T1 (en) 2016-11-18
EP2437606A4 (en) 2012-11-28
EP2437606A1 (en) 2012-04-11
JP5830013B2 (en) 2015-12-09
US20100292197A1 (en) 2010-11-18
CY1118073T1 (en) 2017-06-28
CA2795981A1 (en) 2010-11-25
US9913851B2 (en) 2018-03-13
EP2437606B1 (en) 2016-07-27
SMT201600332B (en) 2016-11-10
DK2437606T3 (en) 2016-09-12
LT2437606T (en) 2016-10-10

Similar Documents

Publication Publication Date Title
HK1246715A1 (en) Compositions and methods for targeted thermomodulation
HK1194071A1 (en) Certain triazolopyrazines, compositions thereof and methods of use therefor
HK1174064A1 (en) Methods and compositions for cell-proliferation-related disorders
EP2437606A4 (en) Compositions and methods for increasing telomerase activity
FI3812360T3 (en) Monochlorotrifluoropropene compounds and compositions and methods using same
EP2406389A4 (en) Methods and compositions for cell-proliferation-related disorders
EP2515946A4 (en) Nanoconjugates and nanoconjugate formulations
EP2483221A4 (en) Fertilizer compositions and methods
IL218212A0 (en) Therapeutic methods and compositions
EP2429584A4 (en) Methods and compositions for treatment
GB0903299D0 (en) Composition and methods
EP2533645A4 (en) Methods and compositions for improving cognitive function
HK1168025A1 (en) Compositions and methods for enhancing eyelashes
EP2490536A4 (en) Compositions and processes
GB0901494D0 (en) Compositions and Methods
EP2461870A4 (en) Therapeutic compositions and methods
ZA201200260B (en) Polyphenylsulphone-polytetrafluroethylene compositions and use thereof
EP2488624A4 (en) Stabilized surfactant-oxidant compositions and related methods
GB0903913D0 (en) Compositions and methods
GB0907616D0 (en) Methods and compositions
GB0909720D0 (en) Compositions and methods
GB0908498D0 (en) Compositions and methods
GB0901899D0 (en) Compositions and uses
GB0902812D0 (en) Composition and use